Not Tagged
morphogenesis,cohbar
['genesis,(-pathogenesis),(-carginogenesis)', 'morphogenesis']
cohbar and morphogenesis announced positive initial results from the phase 1b trial of ifx-hu2.0 in checkpoint inhibitor resistant advanced merkel cell carcinoma (mcc) and cutaneous squamous cell carcinoma (cscc). these data were presented at asco 2023: 
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics.